Sedana Medical’s US Studies Achieve Key Endpoint in Opioid Reduction

Sedana Medical AB ( (SE:SEDANA) ) has shared an update.

Sedana Medical AB announced that its pivotal US studies, INSPiRE-ICU 1 and 2, have successfully met a key secondary endpoint by demonstrating a significant reduction in opioid doses compared to the control group. This achievement supports the company’s aim for US registration of its Sedaconda ACD device and isoflurane for ICU sedation, potentially impacting the US market by providing an alternative to opioid use. The results, which align with previous European studies, will be crucial for the FDA’s assessment of Sedana Medical’s marketing authorization application.

More about Sedana Medical AB

Sedana Medical AB is a pioneering medtech and pharmaceutical company specializing in inhaled sedation to enhance patient experiences during and after sedation. The company offers the Sedaconda ACD medical device and Sedaconda (isoflurane) pharmaceutical for mechanically ventilated patients in intensive care. Sedana Medical operates through direct sales in several European countries and collaborates with distributors in other regions. Founded in 2005, it is listed on Nasdaq Stockholm and headquartered in Stockholm, Sweden.

Average Trading Volume: 715,225

Current Market Cap: SEK1.21B

See more insights into SEDANA stock on TipRanks’ Stock Analysis page.